EuroNanoMedicine 2009 from 28-30 September in Bled
The treatment of diseases such as diabetes, cancer, multiple sclerosis or dementia is also modern medicine still face major challenges. Promising approaches, the "nano", ie the use of tiny particles in the diagnosis and therapy. The latest progress and results are on the EuroNanoMedicine 2009 at 28-30 September 2009 in Bled, Slovenia, by experts from the fields of medicine, nanotechnology, chemistry, cell biology and toxicology are presented and discussed.
Outstanding issues of EuroNanoMedicine 2009, including the body's own barriers to overcome with the help of nanoscale active transport systems, new nano-based diagnostics and Biokompabilität and toxicity of such novel systems. The three-day conference includes, in addition to scientific considerations also political and social aspects of nanomedicine in Europe.
Nanomaterials are primarily known in the industry, for example in the coating of surfaces. In nanomedicine nanoparticles are, inter alia, as drug carriers are used. They should be active against premature degradation on its way through the body or prevent the inclusion in the body easier. By inserting specific biological functions at the nanoscale surface of this vehicle is a directed drug release at the destination can be achieved. This can reduce the effectiveness of the drug increase and decrease side effects.
EuroNanoMedicine organizers of the 2009 is the multidisciplinary NanoBioPharmaceutics Integrated Project together with the projects NanoEar and MediTrans, all three projects will be funded by the European Commission. In NanoBioPharmaceutics have 25 partners from 12 EU countries and Israel together, including 12 universities, six research institutes, four SMEs and three large pharmaceutical companies. The project has a duration of four years and ends in September 2010.
The aim of the project is biodegradable nanoparticle-based transportation systems that provide protein or peptide drugs safely through physiological barriers are transported and released at the destination can be set. For example, a first Alzheimer's medication, the blood-brain barrier pass, which the brain protects against harmful substances. Even for diabetes patients would be a big gain in quality of life mean, it could be diabetes medication orally instead of by injection. Moreover, within nano-BioPharmaceutics new test systems based on cell cultures and investigated with the results from animal experiments compared. The long-term goal here is to find methods that are currently for testing animal testing of drugs prescribed limit, and perhaps someday may replace.
Towards the end of the third year project is under NanoBioPharmaceutics a wide range of nanoparticulate systems have been developed, optimized and are currently on their success and their suitability for the transport of drugs in oral or nasal intake or through the blood-brain barrier to be reviewed.
For more information about NanoBioPharmaceutics and EuroNanoMedicine 2009 are available at